Two Cases of Metastatic Castration‐Resistant Prostate Cancer With Long‐Term Survival Treated With Abiraterone
We report two cases of metastatic castration-resistant prostate cancer (mCRPC) with long-term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression-free for over 5 years, suggesting that some mCRPC patients may achieve durable responses with abiraterone.
Authors
- Ryo Fujiwara (ORCID: https://orcid.org/0000-0001-6566-1430)
- Honoka Fuse
- Minami Une (ORCID: https://orcid.org/0000-0003-3004-4605)
- Junji Yonese (ORCID: https://orcid.org/0000-0001-9266-4020)
- Kenjiro Noda
- Shinya Yamamoto (ORCID: https://orcid.org/0000-0002-8083-5387)
Institutions
- Kin-ikyo Chuo Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/ccr3.71617
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hubei Provincial Department of Education
- Jingchu University of Technology